(91 days)
Not Found
No
The summary describes a spinal implant and an inserter instrument, with no mention of software, algorithms, or any technology related to AI or ML.
Yes
The device is intended to facilitate interbody fusion for patients with degenerative disc disease, which constitutes a therapeutic intervention.
No
The CLYDESDALE® Spinal System is a surgical implant designed for interbody fusion, not for diagnosing medical conditions. It facilitates fusion between vertebral bodies after a diagnosis of degenerative disc disease has already been made.
No
The device description explicitly states the device is manufactured from PEEK and includes Tantalum markers, indicating it is a physical implant and not software only.
Based on the provided text, the CLYDESDALE® Spinal System is not an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use clearly states that the device is designed to be implanted in the body to facilitate interbody fusion in the lumbar spine. This is a surgical implant, not a device used to examine specimens derived from the human body for the purpose of providing information for diagnosis, monitoring, or compatibility testing.
- Device Description: The description details a physical implant made of PEEK with Tantalum markers, designed to be placed between vertebrae. This is consistent with a surgical device.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), reagents, or providing diagnostic information based on such analysis.
Therefore, the CLYDESDALE® Spinal System falls under the category of a surgical implant or medical device, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The CLYDESDALE® Spinal System is designed to be used with autogenous bone graft to facilitate interbody fusion and is intended for use with supplemental fixation systems cleared for use in the lumbar spine. The CLYDESDALE® Spinal System is used for patients diagnosed with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade 1 Spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These implants may be implanted via a minimally invasive lateral approach.
Product codes
MAX
Device Description
The CLYDESDALE® Spinal System consists of a variety of hollow vertebral body spacers featuring a convex, bullet-nosed interbody device designed with an axial void to contain autogenous graft material, and facilitate a fusion between two vertebral bodies. This device is designed with angular teeth to allow the implant to grip the superior and inferior end plates, thus allowing expulsion resistance. The device is manufactured from medical grade polyetheretherketone (PEEK) Optima 1 and includes Tantalum markers for imaging purposes and provided sterile by gamma irradiation. The predicate device is available in a variety of sizes ranging from 8mm to 16mm in height and 40mm to 60mm in length. The purpose of this submission is to add a new Direct Lateral (DL) Inserter instrument to be used with the CL YDESDALE® Spinal System.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Lumbar spine, L2 to S1
Indicated Patient Age Range
Skeletally mature
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
A new Direct Lateral (DL) Inserter instrument was added to the CLYDESDALE® Spinal System and reprocessing instructions for the new instrument were added to the labeling. The subject and predicate CLYDESDALE® Spinal System devices are identical in terms of indications for use, intended use, performance specifications, and technological characteristics. Assessment of the dimensional modifications has been completed in accordance with internal Medtronic processes. Cleaning and sterilization assessments have been conducted to provide the appropriate disassembly, cleaning, and sterilization instructions for the CLYDESDALE® Spinal System. Medtronic believes the information above demonstrates equivalence and supports a determination of substantial equivalence between the subject and predicate CLYDESDALE® Spinal System devices.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3080 Intervertebral body fusion device.
(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
0
page lafa
NOV 2 1 2011
CLYDESDALE® Spinal System 510(k) Summary August 2011
-
I. Company: Medtronic Sofamor Danek 1800 Pyramid Place Memphis, TN 38132 (901) 396-3133
Contact: Julie Bassett Sr. Regulatory Affairs Specialist -
Proprietary Trade Name: CLYDESDALE® Spinal System II.
-
Classification Name: Intervertebral Body Fusion Device (21 CFR 888.3080) III.
-
IV. Product Code: MAX
V. Product Description
The CLYDESDALE® Spinal System consists of a variety of hollow vertebral body spacers featuring a convex, bullet-nosed interbody device designed with an axial void to contain autogenous graft material, and facilitate a fusion between two vertebral bodies. This device is designed with angular teeth to allow the implant to grip the superior and inferior end plates, thus allowing expulsion resistance. The device is manufactured from medical grade polyetheretherketone (PEEK) Optima 1 and includes Tantalum markers for imaging purposes and provided sterile by gamma irradiation. The predicate device is available in a variety of sizes ranging from 8mm to 16mm in height and 40mm to 60mm in length. The purpose of this submission is to add a new Direct Lateral (DL) Inserter instrument to be used with the CL YDESDALE® Spinal System.
Indications VI.
The CLYDESDALE® Spinal System is designed to be used with autogenous bone graft to facilitate interbody fusion and is intended for use with supplemental fixation systems cleared for use in the lumbar spine. The CLYDESDALE® Spinal System is used for patients diagnosed with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade 1 Spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These implants may be implanted via a minimally invasive lateral approach.
1
VII. Substantial Equivalence
Documentation was provided which demonstrated that the subject CLYDESDALE® Spinal System device is substantially equivalent to the predicate CLYDESDALE® Spinal System device cleared in K083026 (SE 12/29/2008) &K100175 (SE 06/02/10).
VIII. Brief Discussion of the Non-Clinical Tests Submitted
A new Direct Lateral (DL) Inserter instrument was added to the CLYDESDALE® Spinal System and reprocessing instructions for the new instrument were added to the labeling. The subject and predicate CLYDESDALE® Spinal System devices are identical in terms of indications for use, intended use, performance specifications, and technological characteristics. Assessment of the dimensional modifications has been completed in accordance with internal Medtronic processes. Cleaning and sterilization assessments have been conducted to provide the appropriate disassembly, cleaning, and sterilization instructions for the CLYDESDALE® Spinal System.
IX. Conclusions Drawn from the Non-Clinical Tests
Medtronic believes the information above demonstrates equivalence and supports a determination of substantial equivalence between the subject and predicate CLYDESDALE® Spinal System devices.
2
Image /page/2/Picture/1 description: The image is a seal for the Department of Health & Human Services - USA. The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is an image of an eagle with its wings spread.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
NOV 2 1 2011
Medtronic Sofamor Danek % Ms. Julie Bassett Sr. Regulatory Affairs Specialist 1800 Pyramid Place Memphis, Tennessee 38132
Re: K112405
Trade/Device Name: CLYDESDALE® Spinal System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX Dated: October 21, 2011 Received: October 24, 2011
Dear Ms. Bassett:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices; good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act
3
Page 2 – Ms. Julie Bassett
or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Erin d Keith
40/ Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
510(k) Number (if known):
112405
Device Name: CLYDESDALE® Spinal System
Indications for Use:
The CLYDESDALE® Spinal System is designed to be used with autogenous bone graft to facilitate interbody fusion and is intended for use with supplemental fixation systems cleared for use in the lumbar spine. The CLYDESDALE® Spinal System is used for patients diagnosed with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade 1 Spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These implants may be implanted via a minimally invasive lateral approach.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Page 1 of 1
(Division Sign-Off)
Dision of Surgical, Orthopedic, and Restorative Devices
KII2405 510(k) Number_